CCL21 (SLC) improves tumor protection by a DNA vaccine in a Her2/neu mouse tumor model

Cancer Gene Therapy

Volumn 19, Issue 1, 2012, Pages 69-76

  Nguyen Hoai, T ^a,b   Baldenhofer, G ^a,b   Sayed Ahmed, M S ^a,b   Pham Duc, M ^a,b   Vu, M D ^a,b   Lipp, M ^b   Dorken B ^a,b   Pezzutto, A ^a,b   Westermann, J ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

CCL21; chemokines; DNA vaccination; Her2 neu; SLC

Indexed keywords

DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PLASMID DNA; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR ANTIGEN;

ADJUVANT THERAPY; ANIMAL CELL; ARTICLE; BAGG ALBINO MOUSE; BREAST CANCER; CANCER ADJUVANT THERAPY; CONTROLLED STUDY; DENDRITIC CELL; DNA IMMUNIZATION; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR MODEL;

ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; CHEMOKINE CCL21; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; VACCINES, DNA;

MUS;

EID: 83555172267     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.69     Document Type: Article

References (37)

1. Stewart TJ, Smyth MJ. Chemokine-chemokine receptors in cancer immunotherapy. Immunotherapy 2009; 1: 109-127.
2. Marsland BJ, Battig P, Bauer M, Ruedl C, Lassing U, Beerli R et al. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 2005; 22: 493-505. (Pubitemid 40545114)
3. Friedman RS, Jacobelli J, Krummel MF. Surface-bound chemokines capture and prime T cells for synapse formation. Nat Immunol 2006; 7: 1101-1108. (Pubitemid 44420655)
4. Worbs T, Mempel TR, Bö lter J, von Andrian UH, Fö rster R. CCR7 ligands stimulate the intranodal motility of T lymphocytes in vivo. J Exp Med 2007; 3: 489-495. (Pubitemid 46457073)
5. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Ann Rev Immunol 2000; 18: 927-974. (Pubitemid 30365401)
6. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007; 25: 267-296. (Pubitemid 46697910)
7. Menard S, Pupa S, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene 2003; 22: 6570-6578. (Pubitemid 37372337)
8. Cavallo F, Offringa R, van der Burg SH, Forni G, Melief CM. Vaccination for the treatment and prevention of cancer in animal models. Adv Immunol 2006; 90: 175-213. (Pubitemid 43765801)
9. Romond EH, Perez EA, Bryant J, Suma VJ, Geyer Jr CE, Davidson NE et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-1680.
10. Curigliano G, Spitaleri G, Pietri E, Rescigno M, de Braud F, Cardillo A et al. Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 2006; 17: 750-762.
11. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S et al. Combined clinical trial results of a Her2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 2008; 14: 797-803. (Pubitemid 351231162)
12. Nagata Y, Furugen R, Hiasa A, Ikeda H, Ohta N, Furukawa K et al. Peptides derived from a wild-type murine proto-oncogene-erbB-2/HER2/neu can induce CTL and tumor suppression in syngeneic hosts. J Immunol 1997; 159: 1336-1343. (Pubitemid 127484112)
13. Piechoski MP, Pilon SA, Wei WZ. Quantitative measurement of anti-ErbB-2 antibody by flow cytometry and ELISA. J Immunol Meth 2002; 259: 33-42. (Pubitemid 33124382)
14. Stevenson FK, Zhu D, Rice J. New strategies for vaccination and imunomodulation in NHL. Ann Hematol 2001; 80 (Suppl 3): B132-B134.
15. Maraskovsky E, Brasel K, Teepe M, Roux ER, Lyman S, Shortman K et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med 1996; 184: 1953-1962. (Pubitemid 26404485)
16. Greenland JR, Letvin NL. Chemical adjuvants for plasmid DNA vaccines. Vaccine 2007; 25: 3731-3741. (Pubitemid 46613830)
17. DellÁ gnola C, Biragyn A. Clinical utilisation of chemokines to combat cancer: the double-edged sword. Exp Rev Vaccines 2007; 6: 267-283. (Pubitemid 46607460)
18. Coscia M, Biragyn A. Cancer immunotherapy with chemoattractant peptides. Sem Cancer Biol 2004; 14: 209-218. (Pubitemid 38586747)
19. Scheerlinck JP. Genetic adjuvants for DNA vaccines. Vaccine 2001; 19: 2647-2656.
20. Gunn MD, Kyuwa S, Tam C, Kakiuchi T, Matsuzawa A, Williams LT et al. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. J Exp Med 1999; 189: 451-460. (Pubitemid 29187367)
21. Ricart BG, John B, Lee D, Hunter AC, Hammer DA. Dendritic cells distinguish individual chemokine signals through CCR7 and CXCR4. J Immunol 2011; 186: 53-61.
22. Wei WZ, Shi WP, Galy A, Lichlyter D, Hernandez S, Groner B et al. Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 1999; 81: 748-754. (Pubitemid 29214385)
23. Kiessling R, Wei WZ, Herrmann F, Lindencrona JA, Choudhury A, Kono K et al. Cellular immunity to the Her-2/neu protooncogene. Adv Cancer Res 2002; 85: 101-144.
24. Lindencrona JA, Preise S, Kammertö ns T, Schü ler T, Piechocki M, Wei WZ et al. CD4+ T cell-mediated Her-2/neu-specific tumor rejection in the absence of B cells. Int J Cancer 2004; 109: 259-264. (Pubitemid 38240929)
25. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu Rev Immunol 1995; 13: 399-415.
26. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and longlasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543. (Pubitemid 23111402)
27. Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH et al. The CC chemokine CKb-11/MIP-3b/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164: 4025-4031. (Pubitemid 30215056)
28. Beauvillain C, Cunin P, Doni A, Scotet M, Jaillon S, Loiry ML et al. CCR7 is involved in the migration of neutrophils to lymph nodes. Blood 2011; 117: 1196-1204.
29. Gunn MD, Tangemann K, Tam C, Cyster JG, Rosen SD, Williams LT. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naive lymphocytes. Proc Natl Acad Sci USA 1998; 95: 258-263. (Pubitemid 28103941)
30. Martin-Fontecha AS, Sebastiani S, Hö pken UE, Uguccioni M, Lipp M, Lanzavecchia A et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J Exp Med 2003; 198: 615-621. (Pubitemid 37040395)
31. Sallusto F, Palermo B, Lenig D, Miettinen M, Matikaine S, Julkunen I et al. Distinct patterns and kinetics of chemokine production regulate dendritic cell function. Eur J Immunol 1999; 29: 1617-1625. (Pubitemid 29224467)
32. Radstake TR, van der Voort R, ten Brummelhuis M, de Waal Melefijt M, Looman M, Figdor CG et al. Increased expression of CCL18, CCL19 and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors. Ann Rheum Dis 2005; 64: 359-367. (Pubitemid 40283044)
33. Sharma S, Stolin M, Luo J, Strieter RM, Burdick M, Zhu LX et al. Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo. J Immunol 2000; 164: 4558-4563. (Pubitemid 30238052)
34. Sharma S, Stolina M, Zhu L, Lin Y, Batra R, HuangMet al. Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2001; 61: 6406-6412. (Pubitemid 32783246)
35. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM et al. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 2006; 66: 3205-3213.
36. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M et al. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity. Cancer Res 2004; 10: 2891-2901. (Pubitemid 38509169)
37. Qin H, Zhou C, Wang D, Ma W, Liang X, Lin C et al. Enhancement of antitumour immunity by a novel chemotactic antigen DNA vaccine encoding chemokines and multiepitopes of prostate-tumour-associated antigens. Immunology 2006; 117: 419-430.